The efficacy of botulinum toxin in disabling multiple sclerosis (MS) tremor

Title
The efficacy of botulinum toxin in disabling multiple sclerosis (MS) tremor

Type of intervention
Drug

Form of MS
Relapsing-remitting, secondary progressive

Brief summary
The incidence of tremor in Multiple Sclerosis (MS) has been estimated to affect up to 2/3rds of patients. Over half of the tremors involve the upper limb and frequently lead to further disability. Medical treatment of MS tremor is generally unrewarding, although carbamazepine, clonazepam, glutethimide, hyoscine, isoniazid, ondansetron, primidone, and tetrahydrocannabinol have been reported to have some beneficial effect but published evidence of effectiveness is very limited. The investigators' experience to date suggests that many of the upper limb tremors may potentially be responsive to Botulinum toxin injection therapy.

Inclusion criteria

• Relapsing-remitting MS or secondary progressive MS according to the Mc Donald criteria
• Age 18-80 years of age
• Competent to understand and sign informed consent
• Presence of symptomatic head and/or limb tremor

Anticipated start date

Recruitment status
Closed

Recruitment contacts
anneke.vanderwalt@mh.org.au

Further details
http://clinicaltrials.gov/ct2/show/NCT01018485?term=multiple+sclerosis&recr=Open&cntry1=PA%3AAU&rank=7

Region
VIC, NSW

Trial results

Last updated: May 2011